- Home
- OPRT vs PBYI Comparison
OPRT vs PBYI Comparison
Compare OPRT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRT | PBYI |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 263.4M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | OPRT | PBYI |
|---|---|---|
| Price | $4.88 | $6.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.25 | $7.00 |
| AVG Volume (30 Days) | ★ 574.8K | 478.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.18 | N/A |
| EPS | 0.53 | ★ 0.61 |
| Revenue | ★ $956,685,000.00 | $27,685,000.00 |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $6.73 | N/A |
| P/E Ratio | ★ $9.68 | $9.93 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.06 | $2.58 |
| 52 Week High | $7.73 | $7.68 |
Technical Indicators
Market Signals| Indicator | OPRT | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 42.97 |
| Support Level | $4.63 | $5.57 |
| Resistance Level | $5.68 | $7.25 |
| Average True Range (ATR) | 0.32 | 0.45 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 8.98 | 26.61 |
Price Performance
Historical ComparisonAbout OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.